Company intelligence / Profile preview

BiOneCure Therapeutics Inc.

Germantown, Maryland, United Statesbionecure.com ↗

Ownership: Private
Development stage: Phase 1

Overview

BIO-106, an anti-Trop-2 ADC, is currently in Phase I/II clinical trials (StarBridge-1) to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity as monotherapy and in combination with pembrolizumab in patients with advanced cancers[6][8].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Monoclonal antibodiesBispecific antibodies
Industry: Biotech

Drug pipeline

6 assets

bio-106

5 more assets in the full pipeline.

Request access →

Partnerships

Nanjing Leads Biolabs

Beyond the preview

Go deeper on BiOneCure Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiOneCure Therapeutics Inc..

Explore the full profile